ClinicalTrials.gg
RecruitingNCT06646276Updated Nov 10, 2026

A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

A Phase 3 interventional study of BMS-986489 (Atigotatug+Nivolumab) and Atezolizumab in Extensive-Stage Small Cell Lung Cancer, sponsored by Bristol-Myers Squibb. Recruiting at 183 sites in 26 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 8 months later.
Updated Nov 10, 2026Site recruiting status changedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
530
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies in Small Cell Lung Carcinoma by Bristol-Myers Squibb — 2 open to participants now, 2 under way, 1 of them phase 3. Small Cell Lung Carcinoma · Bristol-Myers Squibb.

Planned enrollment
3rd of 17
530 · median 92
Started
2025
with 1 other
Phase 3
3 of 19
1 open now
Registered
17th of 19
by date

Among the 19 studies in Small Cell Lung Carcinoma by Bristol-Myers Squibb, this one is the 3rd largest by planned enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2025, is one of 3 in phase 3, and was the 17th registered.

Small Cell Lung Carcinoma

1,302 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

2 of the 19 studies in Small Cell Lung Carcinoma by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Small Cell Lung Carcinoma by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

The Purpose of the Study is to Compare the Efficacy and Safety of BMS-986489 (Anti-fucosyl-GM1+ Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide to that of Atezolizumab with Carboplatin plus Etoposide as First-Line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer.

03

Conditions studied

  • Extensive-Stage Small Cell Lung Cancer

Keywords

  • BMS-986489
  • BMS-986012
  • Extensive-Stage Small Cell Lung Cancer
  • Etoposide
  • Carboplatin
  • Nivolumab
  • TIGOS
  • fucGM1
  • SCLC
  • ES-SCLC
  • atigotatug
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have diagnosis of Extensive-Stage Small Cell Lung Cancer (ES-SCLC).
  • Participants must be Healthy enough to do their normal activities with little or no help based on the performance scale.
  • Participants must have at least one tumor that can be measured using special imaging techniques like a CT scan or MRI at a site other than the brain and nervous system

Exclusion criteria

Exclusion Criteria

  • Participants have already received certain types of treatment for extensive stage small cell lung cancer
  • Participants have certain health conditions, like spread of small cell lung cancer to the brain that are causing symptoms, certain lung diseases, heart diseases, infections, diseases, other cancers, or a type of nerve damage called peripheral sensory neuropathy
  • Other protocol-defined Inclusion/Exclusion criteria apply.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
530 participants (estimated)

Study arms

  • Experimental
    Arm A

    Biological: BMS-986489 (Atigotatug+Nivolumab) · Drug: Carboplatin · Drug: Etoposide

  • Active comparator
    Arm B

    Biological: Atezolizumab · Drug: Carboplatin · Drug: Etoposide

Interventions

This study also gives Nivolumab. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    Time frame: Up to 5 years

Secondary outcomes

  1. Time to definitive deterioration (TTDD)based on the LCSS ASBI defined as the time from randomization until a definitive clinically meaningful decline (≥ 10 point increase from baseline in LCSS ASBI score).

    Time frame: Up to 5 years

  2. Number of participants with Adverse Events (AEs)

    Time frame: Up to 135 days after last treatment

  3. Number of Participants with Serious Adverse Events (SAEs)

    Time frame: Up to 135 days after last treatment

  4. Number of Participants with Adverse Events (AEs) leading to discontinuation and death

    Time frame: Up to 135 days after last treatment

  5. Objective Response (OR)

    Time frame: Up to 5 years

  6. Duration of Response (DOR)

    Time frame: Up to 5 years

  7. Progression Free Survival (PFS)

    Time frame: Up to 5 years

07

Study locations

18 of 183 sites recruiting
  • Southern Cancer Center, PC
    Daphne, Alabama 36526, United States
    Recruiting
    • Michael Meshad, Site 0337 · Contact111-111-1111
  • Local Institution - 0283
    Hot Springs, Arkansas 71913, United States
    Completed

    Not enrolling at this site — choose another above.

  • Florida Cancer Specialists - South
    Fort Myers, Florida 33901, United States
    Recruiting
    • Alexander Glick, Site 0245 · Contact239-274-9930
  • Mid Florida Hematology and Oncology Center
    Orange City, Florida 32763, United States
    Recruiting
    • Santosh Nair, Site 0009 · Contact407-353-1915
  • Florida Cancer Specialists - North
    St. Petersburg, Florida 33705, United States
    Recruiting
    • Maen Hussein, Site 0020 · Contact727-216-1143
  • Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital
    Marietta, Georgia 30060, United States
    Recruiting
    • Walid Shaib, Site 0013 · Contact770-281-5124
  • Illinois Cancer Care
    Peoria, Illinois 61615, United States
    Recruiting
    • Gary MacVicar, Site 0019 · Contact309-243-3000
  • Local Institution - 0037
    Minneapolis, Minnesota 55407, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • University of New Mexico Comprehensive Cancer Center
    Albuquerque, New Mexico 87106, United States
    Recruiting
    • Moises Harari-Turquie, Site 0033 · Contact505-570-5835
  • Duke Cancer Institute
    Durham, North Carolina 27710, United States
    Recruiting
    • Neal Ready, Site 0029 · Contact919-684-8239
  • Sanford Medical Center
    Bismarck, North Dakota 58501, United States
    Recruiting
    • Thandiwe Gray, Site 0232 · Contact701-323-5741
  • Sanford Fargo Medical Center
    Fargo, North Dakota 58102, United States
    Recruiting
    • Mark Gitau, Site 0010 · Contact000-000-0000
  • Oncology Hematology Care
    Cincinnati, Ohio 45242, United States
    Recruiting
    • Patrick Ward, Site 0284 · Contact513-751-2273
  • Sanford Cancer Center
    Sioux Falls, South Dakota 57104, United States
    Recruiting
    • Allison Watson, Site 0231 · Contact605-209-4092
  • SCRI Oncology Partners
    Nashville, Tennessee 37203, United States
    Recruiting
    • Melissa Johnson, Site 0008 · Contact615-329-7274
  • Texas Oncology - Central/South Texas
    Austin, Texas 78705, United States
    Recruiting
    • James Uyeki, Site 0001 · Contact512-427-9400
  • Texas Oncology - Northeast Texas
    Tyler, Texas 75702, United States
    Recruiting
    • Sarah Wang, Site 0281 · Contact903-579-9800
  • Oncology & Hematology Associates of Southwest Virginia, Inc.
    Roanoke, Virginia 24014, United States
    Recruiting
    • Jerome Goldschmidt, Site 0246 · Contact540-381-5291
  • Swedish Cancer Institute - Edmonds
    Edmonds, Washington 98026, United States
    Recruiting
    • Siddhartha Devarakonda, Site 0339 · Contact206-386-2457
  • Swedish Medical Center
    Seattle, Washington 98104, United States
    Recruiting
    • Siddhartha Devarakonda, Site 0026 · Contact206-386-2457
  • Local Institution - 0079
    Ciudad Autónoma de Buenos Aires, Buenos Aires C1426ANZ, Argentina
    Completed

    Not enrolling at this site — choose another above.

  • Local Institution - 0077
    ABB, Buenos Aires F.D. C1199ABB, Argentina
    Completed

    Not enrolling at this site — choose another above.

  • Local Institution - 0100
    Buenos Aires, Buenos Aires F.D. C1417DTB, Argentina
    Withdrawn

    Not enrolling at this site — choose another above.

  • Local Institution - 0080
    CABA, Buenos Aires F.D. C1430EGF, Argentina
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 0094
    Río Cuarto, Córdoba Province X5800AEV, Argentina
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 0202
    Campbelltown, New South Wales 2560, Australia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 0106
    Penrith, New South Wales 2750, Australia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 0105
    Brisbane, Queensland 4120, Australia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 0190
    Ballarat Central, Victoria 3350, Australia
    Completed

    Not enrolling at this site — choose another above.

  • Local Institution - 0175
    Murdoch, Western Australia 6150, Australia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 0253
    Graz, Styria 8036, Austria
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 0251
    Wels, Upper Austria 4600, Austria
    Completed

    Not enrolling at this site — choose another above.

  • Local Institution - 0252
    Linz, 4021, Austria
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 0255
    Rankweil, 6830, Austria
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 0198
    Brussels, Bruxelles-Capitale, Région de 1200, Belgium
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 0091
    Ghent, Oost-Vlaanderen 9000, Belgium
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 0187
    Sint-Niklaas, Oost-Vlaanderen B-9100, Belgium
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 0092
    Liège, 4000, Belgium
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 0166
    Fortaleza, Ceará 60135-237, Brazil
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 0165
    Porto Alegre, Rio Grande do Sul 90035-903, Brazil
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 0169
    Porto Alegre, Rio Grande do Sul 90610-000, Brazil
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 0170
    Santa Cruz do Sul, Rio Grande do Sul 96830-180, Brazil
    Completed

    Not enrolling at this site — choose another above.

  • Local Institution - 0163
    Itajaí, Santa Catarina 88301-220, Brazil
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 0178
    Barretos, São Paulo 14784400, Brazil
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 0111
    São Paulo, São Paulo 01509-010, Brazil
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 0289
    Edmonton, Alberta T6G 1Z2, Canada
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 0290
    Chicoutimi, Quebec G7H 5H6, Canada
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 0288
    Québec, Quebec G1V 4G5, Canada
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 0287
    Rimouski, Quebec G5L 5T1, Canada
    Completed

    Not enrolling at this site — choose another above.

  • Local Institution - 0086
    Santiago, Santiago Metropolitan 0, Chile
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 0085
    Santiago, Santiago Metropolitan 7500921, Chile
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 0083
    Santiago, Santiago Metropolitan 8330032, Chile
    Completed

    Not enrolling at this site — choose another above.

  • Local Institution - 0084
    Santiago, Santiago Metropolitan 8420383, Chile
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 0082
    Viña del Mar, Valparaiso 2520598, Chile
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 0204
    Beijing, Beijing Municipality 100142, China
    Completed

    Not enrolling at this site — choose another above.

  • Local Institution - 0336
    Beijing, Beijing Municipality 101149, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 0203
    Chongqing, Chongqing Municipality 400030, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 0308
    Fuzhou, Fujian 350014, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 0212
    Xiamen, Fujian 361003, China
    Completed

    Not enrolling at this site — choose another above.

  • Local Institution - 0234
    Shantou, Guangdong 515000, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 0227
    Harbin, Heilongjiang 150081, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 0209
    Wuhan, Hubei 430079, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 0208
    Wuhan, Hubei 430100, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 0216
    Changsha, Hunan 410013, China
    Completed

    Not enrolling at this site — choose another above.

  • Local Institution - 0233
    Nanchang, Jiangxi 330006, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 0244
    Changchun, Jilin 132000, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 0235
    Shenyang, Liaoning 110042, China
    Not yet recruiting
    • Site 0235 · Contact
  • Local Institution - 0335
    Xi'an, Shaanxi 710126, China
    Completed

    Not enrolling at this site — choose another above.

  • Local Institution - 0200
    Jinan, Shandong 250117, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 0206
    Shanghai, Shanghai Municipality 200030, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 0210
    Shanghai, Shanghai Municipality 200032, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 0186
    Shanghai, Shanghai Municipality 200120, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 0330
    Chengdu, Sichuan 610041, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 0213
    Tianjin, Tianjin Municipality 300060, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 0236
    Hangzhou, Zhejiang 310016, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 0237
    Hangzhou, Zhejiang 310022, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 0229
    Linhai, Zhejiang 317000, China
    Completed

    Not enrolling at this site — choose another above.

  • Local Institution - 0114
    Brno, Brno-město 656 53, Czechia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 0117
    Ostrava, Ostrava Město 703 00, Czechia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 0113
    Prague, Praha 4 14059, Czechia
    Completed

    Not enrolling at this site — choose another above.

  • Local Institution - 0116
    Olomouc, 779 00, Czechia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 0048
    Montpellier, Hérault 34090, France
    Completed

    Not enrolling at this site — choose another above.

  • Local Institution - 0040
    La Tronche, Isère 38700, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 0052
    Lille, Nord 59037, France
    Completed

    Not enrolling at this site — choose another above.

  • Local Institution - 0044
    Gleizé, Rhône 69400, France
    Completed

    Not enrolling at this site — choose another above.

  • Local Institution - 0051
    Pierre-Bénite, Rhône 69310, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 0047
    Créteil, Val-de-Marne 94010, France
    Completed

    Not enrolling at this site — choose another above.

  • Local Institution - 0038
    Villejuif, Val-de-Marne 94800, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 0043
    Marseille, 13915, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 0050
    Paris, 75248, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 0215
    Quimper, 29000, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 0256
    Frankfurt am Main, Hesse 60488, Germany
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 0262
    Oldenburg, Lower Saxony 26121, Germany
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 0261
    Cologne, North Rhine-Westphalia 51109, Germany
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 0265
    Halle, Saxony-Anhalt 06120, Germany
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 0257
    Bad Berka, Thuringia 99437, Germany
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 0258
    Gauting, 82131, Germany
    Completed

    Not enrolling at this site — choose another above.

  • Local Institution - 0259
    Großhansdorf, 22927, Germany
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 0260
    Heidelberg, 69126, Germany
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 0264
    Stuttgart, 70736, Germany
    Active, not recruiting

    Not enrolling at this site — choose another above.

Showing the first 100 of 183 sites across 26 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Aug 2027, 29 months after the start.

Of 55 industry-sponsored phase 3 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 44. This study's planned 29 months is below that.

Counting every sponsor, half of 68 studies reached it within 41 months; a quarter within 31 and three quarters within 48.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: primary completion Apr 2028 → Aug 2027 and completion Sep 2031 → Jul 2031.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2024
First posted
Oct 17, 2024
StartActual
Feb 25, 2025
Primary completionEst.
Aug 17, 2027was Apr 2028
CompletionEst.
Jul 14, 2031was Sep 2031
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
8 sites changed recruiting status (7 now completed, 1 now active, not recruiting)
Show 8 sites
  • Local Institution - 0216 · Changsha, ChinaActive, not recruiting→Completed
  • Local Institution - 0229 · Linhai, ChinaActive, not recruiting→Completed
  • Local Institution - 0273 · Kolkata, IndiaActive, not recruiting→Completed
  • Local Institution - 0070 · Peschiera del Garda, ItalyActive, not recruiting→Completed
  • Local Institution - 0113 · Prague, CzechiaActive, not recruiting→Completed
  • Local Institution - 0326 · Bunkyo-ku, JapanActive, not recruiting→Completed
  • Local Institution - 0310 · Kuala Lumpur, MalaysiaCompleted→Active, not recruiting
  • Local Institution - 0158 · Çiğli, Turkey (Türkiye)Active, not recruiting→Completed
across 2 updates, Oct 13, 2026 – Nov 10, 2026
Primary completion
Apr 6, 2028→Aug 17, 2027
Oct 13, 2026
Study completion
Sep 5, 2031→Jul 14, 2031
Oct 13, 2026
Show all 2 updates
  1. Nov 10, 2026
    4 sites changed recruiting status (3 now completed, 1 now active, not recruiting)
    Show 4 sites
    • Local Institution - 0113 · Prague, CzechiaActive, not recruiting→Completed
    • Local Institution - 0326 · Bunkyo-ku, JapanActive, not recruiting→Completed
    • Local Institution - 0310 · Kuala Lumpur, MalaysiaCompleted→Active, not recruiting
    • Local Institution - 0158 · Çiğli, Turkey (Türkiye)Active, not recruiting→Completed
    + 1 other change: verification date
  2. Oct 13, 2026
    4 sites changed recruiting status (4 now completed)
    Show 4 sites
    • Local Institution - 0216 · Changsha, ChinaActive, not recruiting→Completed
    • Local Institution - 0229 · Linhai, ChinaActive, not recruiting→Completed
    • Local Institution - 0273 · Kolkata, IndiaActive, not recruiting→Completed
    • Local Institution - 0070 · Peschiera del Garda, ItalyActive, not recruiting→Completed
    Primary completion Apr 6, 2028→Aug 17, 2027
    Study completion Sep 5, 2031→Jul 14, 2031
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06646276
Responsible party
Sponsor
First posted
Oct 17, 2024
Start date
Feb 25, 2025
Primary completion
Aug 17, 2027 (estimated)
Completion
Jul 14, 2031 (estimated)
Last update
Nov 10, 2026

Study contacts

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Contact
Clinical.Trials@bms.com
855-907-3286
First line of the email MUST contain NCT # and Site #.
Contact
Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atigotatug/Nivolumab

Start the discussion